Empagliflozin Improves Beta Cell Function Compared With Insulin in T2DM Tags SGLT-2 Inhibitor Read more about Empagliflozin Improves Beta Cell Function Compared With Insulin in T2DM
Metabolic Risk Reduction Achieved After Kidney Transplant With GLP-1 and SGLT2 Agents Tags SGLT-2 Inhibitor Read more about Metabolic Risk Reduction Achieved After Kidney Transplant With GLP-1 and SGLT2 Agents
A Single Daily Combination Therapy Improves Cardiometabolic Measures in T2DM Read more about A Single Daily Combination Therapy Improves Cardiometabolic Measures in T2DM
Luseogliflozin Improves Glycemic Metrics and Metabolic Outcomes in T2DM Read more about Luseogliflozin Improves Glycemic Metrics and Metabolic Outcomes in T2DM
Semaglutide Shows Potential Anti-Inflammatory Benefit in T2DM Read more about Semaglutide Shows Potential Anti-Inflammatory Benefit in T2DM
Hormone Profiles Highlight Variation in Dulaglutide Response Read more about Hormone Profiles Highlight Variation in Dulaglutide Response
Fixed-Dose Combination Therapy Enhances Glycemic and Renal Outcomes in T2DM With CKD Read more about Fixed-Dose Combination Therapy Enhances Glycemic and Renal Outcomes in T2DM With CKD
Tirzepatide Leads Once-Weekly GLP-1 Class in Glycemic and Weight Outcomes Read more about Tirzepatide Leads Once-Weekly GLP-1 Class in Glycemic and Weight Outcomes
GLP-1 Receptor Agonists Provide Consistent Cardiovascular and Renal Benefit Across Drug Class Read more about GLP-1 Receptor Agonists Provide Consistent Cardiovascular and Renal Benefit Across Drug Class
SGLT2 Inhibitors Improve Outcomes in CKD Regardless of Diabetes or Albuminuria Severity Tags SGLT-2 Inhibitor Read more about SGLT2 Inhibitors Improve Outcomes in CKD Regardless of Diabetes or Albuminuria Severity